Nivalis Therapeutics, Inc. (ALPN)
(Delayed Data from NSDQ)
$6.24 USD
-0.08 (-1.27%)
Updated May 3, 2019 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALPN 6.24 -0.08(-1.27%)
Will ALPN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALPN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALPN
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates
Vertex's (VRTX) Q1 Earnings Beat, Trikafta Drives Sales
ALPN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex